 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
 |
|
|
||
About
HIFU |
||
|
About
Ablatherm |
||
Clinical
Information 
Indications
Histology
MRI
Post Treatment
PSA
Post Treatment |
||
|
Clinical
Results |
||
|
Clinical
Trials |
||
|
||
|
Video
Clips |
||
 |
| You are here : Physicians > HIFU - Ablatherm > Clinical Information > Indications |
 |
|
|
Clinically Localized Prostate Cancer: • First choice therapy (T1, T2) The Ablatherm is the first HIFU device to have obtained the CE mark for treatment of prostate cancer in 2000. The Ablatherm is also approved for these indications in Europe, Canadia, Australia, Russia and South Korea.
|
|
® Ablatherm
is aregistered trademark of EDAP.
© Copyright 2007 EDAP. All rights reserved. |